Clinical Trial Update: Identification of Early Markers of Response and Resistance to Trastuzumab [NA]

View source ↗

Summary

This document reports the completion of a clinical trial investigating early markers of response and resistance to trastuzumab in untreated HER2-positive breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer | NA | Status: COMPLETED